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Abstract
AIM: To determine the prevalence of a new set of 
anti-glycan and anti-outer membrane protein (anti-
OMP) antibodies in a Hungarian cohort of adult Celiac 
disease (CD) patients. 
METHODS: 190 consecutive CD patients [M/F: 
71/119, age:39.9 (SD:14.1) years], 100 healthy, and 
48 gastrointestinal controls were tested for glycan anti-
Saccharomyces cerevisiae (gASCA), anti-laminaribioside 
(ALCA), anti-chitobioside, anti-mannobioside, anti-OMP 
antibodies and major NOD2/CARD15 mutations. Thirty 
out of 82 CD patients enrolled at the time of diagnosis 
were re-evaluated for the same antibodies after 
longstanding gluten-free diet (GFD). 
RESULTS: 65.9% of the CD patients were positive 
for at least one of the tested antibodies at the time 
of the diagnosis. Except anti-OMP and ALCA, anti-
microbial antibodies were exclusively seen in untreated 
CD; however, the overall sensitivity was low. Any 
glycan positivity (LR+: 3.13; 95% CI: 2.08-4.73) 
was associated with an increased likelihood ratio 
for diagnosing CD. Significant correlation was found 
between the levels of anti-glycan and anti-endomysial 
or anti-transglutaminase antibodies. Anti-glycan 
positivity was lost after longstanding GFD. Anti-glycan 
antibody titers were associated with symptoms at 
presentation, but not the presence of NOD2/CARD15 
mutations. Patients with severe malabsorption more 
frequently had multiple antibodies at diagnosis (P  = 
0.019). 
CONCLUSION: The presence of anti-glycan antibodies 
in CD seems to be secondary to the impaired small bowel 
mucosa which can lead to increased antigen presentation. 
Furthermore, anti-glycan positivity may be considered an 
additional marker of CD and dietary adherence.
© 2009 The WJG Press and Baishideng. All rights reserved.
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INTRODUCTION
Celiac disease (CD) is a genetically determined chronic 
inflammatory disorder with autoimmune components 
induced by exposure to gluten[1]. The clinical presenta-
tion of  the disease is highly variable and little is known 
about the factors that determine the type of  symptoms. 
The inflamed and damaged small bowel mucosa as well 
as the clinical symptoms shows recovery in most affected 
subjects after a complete removal of  gluten from their 
diet[2]. The presence of  different autoantibodies is a typi-
cal feature of  CD; however, the exact mechanism be-
hind their production and potential role in the disease 
pathogenesis has not yet been fully understood[3]. Tissue 
transglutaminase 2 (TG2) is the main autoantigen of  anti-
endomysial antibodies (EMA) and anti-TG2/EMA are 
commonly used for screening and diagnosing CD[4]. More 
recently antibodies directed against synthetic deamidated 
gliadin peptides have also been suggested as a reliable tool 
for diagnosing CD[5]. Most of  the other antibodies do not 
appear to have either high sensitivity or specificity for CD, 
but they may be associated with specific clinical presenta-
tions or extra-intestinal manifestations[6]. As a sign of  the 
cytoskeleton and intercellular tight junction involvement, 
a high prevalence of  IgA anti-actin antibodies was also 
reported which strongly correlated with the degree of  
villous atrophy, appearing in more severe forms of  the 
disease[7]. Furthermore, production of  anti-actin antibod-
ies was gluten dependent. After strict adherence to gluten-
free diet (GFD), they become undetectable within several 
months indicating that their appearance follows mucosal 
injury[8,9]. Similarly, also the occurrence of  anti-zonulin 
antibodies was associated with active CD and disappear-
ing during remission[10].
The presence of  serological responses to various 
microbial antigens [e.g. phosphopeptidomannan cell-
wall component of  anti-Saccharomyces cerevisiae 
(ASCA), outer membrane porin C transport protein of  
the Escherichia coli (OmpC) or the Pseudomonas fluorescens 
associated protein I2] is characteristic of  Crohn’s disease 
and has been intensively studied for its clinical value in 
this patient group[11]. The occurrence and magnitude of  
the seroreactivity are associated with complicated small 
bowel disease and the need for surgical intervention[12,13]. 
More recently, antibody formations against different gly-
cans, which are common structures in the glycocalyx of  
pathogenic yeast and bacteria[14], have also been reported 
in this patient group. Our group demonstrated that with 
the use of  anti-glycan (g)ASCA and a panel of  novel 
anti-glycan antibodies [anti-mannobioside (AMCA), anti-
laminaribioside (ALCA), and anti-chitobioside (ACCA)], 
gave the same conclusions. Additionally, we evaluated 
the performance of  all four anti-glycan antibodies and 
the traditional combination of  ASCA IgG and IgA. Both 
panels equally identified 59.4% of  all Crohn’s disease 
patients. Eighty percent of  these identified cases were 
the same patients while the remaining 10%-10% were 
detected by only one of  the panels[15].
Despite the fact that the exact mechanism behind 
antibody formation or their possible relevance in the 
pathogenesis still needs to be elucidated, current data 
suggest that these markers are not an epiphenomenon 
related to the inflamed, leaky bowel mucosa[16-18] but 
reflect a loss of  tolerance toward bacterial and fungal 
flora[19]. Furthermore, the anti-microbial antibodies 
might represent genetic susceptibility because patients 
who have positive antibodies often carry mutations in 
the NOD2/CARD15 gene[11,20,21].
Anti-microbial antibody formation has also been re-
ported in CD. ASCAs remain the most widely investigated 
antibodies[22-26] in this patient group but increasing experi-
mental data are available on newly discovered antibodies 
such as anti-I2 or anti-OmpW (Bacteroides caccae TonB-
linked outer membrane protein)[27,28]. The frequency of  
ASCA varied from 27% to 59% in various studies, owing 
to the differences in the number and the age of  the pa-
tients as well as the commercial assays used for antibody 
detection. The frequency of  seropositivity and serum lev-
els of  these antibodies clearly decreased during GFD.
We hypothesized that newly discovered inflammatory 
bowel disease (IBD)-associated antibodies (including 
anti-glycan antibodies and anti-OMP) may also be of  im-
portance in CD and aimed to determine the prevalence 
of  these antibodies in a Hungarian cohort of  adult CD 
patients in relation to clinical presentation, GFD and 
NOD2/CARD15 mutations.
MATERIALS AND METHODS
Patients
One-hundred and ninety consecutive, unrelated Hungar-
ian adult patients with biopsy-proven CD (male/female: 
71/119, mean age: 39.9 years, SD: 14.1) and 66 of  their 
first degree relatives (siblings, mean age: 37.7 years, SD: 
13.9) were investigated. The diagnosis of  CD was based 
on small bowel biopsy showing severe villous atrophy 
with crypt hyperplasia (Marsh type Ⅲ lesions)[29] and 
elevated serum levels of  antibodies against transgluta-
minase (TGA) and endomysium (EMA). IgA and IgG 
class EMA were investigated on human umbilical cord 
substrate using indirect immunofluorescence method as 
previously described[30]. TGA were measured by enzyme-
linked immunosorbent assay (ELISA) using human 
recombinant antigen expressed in Escherichia coli[31,32].
Of  the 190 patients, 82 patients’ sera were obtained 
at the time of  diagnosis (Group CD1) and in 30 of  these 
82 patients further serum samples were re-evaluated for 
the same antibodies after adherence to long-standing 
GFD. The median follow-up period between these 
blood samplings was 28.5 mo [interquartile range (IQR): 
18-52]. In the 108 remaining cases the diagnosis of  CD 
had been established prior to this study and they adopted 
a strict GFD. These 108 patients were divided into two 
separate groups according to their current TGA and 
EMA status and dietary compliance at the time of  the 
sampling. Thirty-three patients still had positive EMA 
and TGA results (Group CD2) and the median duration 
was here 3.5 mo (IQR: 1-11). The adequate compliance 
was indicated by reduced antibody titers as compared 
to those at diagnosis. The remaining 75 patients had 
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negative EMA and normal TGA titers (Group CD3), 
median follow up: 21 mo (IQR: 6-85).
Detai led cl inical data concerning the cl inical 
presentation of  CD at diagnosis were classified as follows: 
(1) severe generalized malabsorption (presence of  at least 
four of  the following five symptoms: diarrhea, abdominal 
distension, weight loss, anemia, hypoproteinemia); 
(2) non-specific gastrointestinal symptoms that did 
not compromise the general condition (diarrhea, 
constipation, bloating, recurrent abdominal pain or 
vomiting, esophageal reflux); (3) iron deficiency anemia 
without major gastrointestinal complaints; (4) dermatitis 
herpetiformis; (5) silent disease (population screening); 
(6) other (autoimmune diseases, reduced bone mineral 
density, liver disease, brain disease). Patients were assigned 
to one of  these major presentation types in a prospective 
manner, based on clinical and routine laboratory results at 
diagnosis.
The control group consisted of  100 healthy, ethnically 
similar, blood donor individuals (male/female: 47/53, 
mean age: 36.6 years, SD: 9.1) who had normal findings 
on a thorough medical examination, blood pressure mea-
surements, and routine laboratory tests. A second non-
celiac gastrointestinal disease control group consisted of  
48 patients with irritable bowel syndrome/diverticulosis 
without inflammation (male/female: 21/26, mean age 
40.4 years, SD: 16.1). In controls, CD was excluded by 
the negativity of  EMA and TGA. None of  the control 
subjects had a family history of  CD. Further comparisons 
were made with the previously published Crohn’s disease 
cohort we investigated for the same antibodies earlier[15].
The study protocol was approved by the Regional 
and Institutional Committee of  Science and Research 
Ethics of  the University of  Debrecen (DEOEC RKEB/
IKEB: 2600-2007). Informed consent was obtained 
from all patients and controls.
Anti-microbial antibody assays
gASCA IgG, AMCA IgG, ALCA IgG, ACCA IgA (IBDX®, 
Glycominds Ltd., Lod, Israel), ASCA IgG, ASCA IgA 
and OMP IgA (QUANTA Lite™ OMP PLUS, INOVA 
Diagnostics, San Diego, CA) were measured in sera 
according to the manufacturers’ protocols. The results 
were presented as arbitrary units, which were calculated 
based on sample and calibrator optical density. Cut-
off  levels used for the determination of  positivity were 
according to the manufacturers’ guidelines: 50, 100, 60 
and 90 U/mL for gASCA IgG, AMCA IgG, ALCA IgG, 
ACCA IgA, respectively, and 25 U/mL for ASCA IgG, 
ASCA IgA and OMP IgA.
Detection of NOD2/CARD15 mutations
One-hundred and thirty-four CD patients and 100 healthy 
control subjects were eligible for NOD2/CARD15 
mutation analysis. Major NOD2/CARD15 mutations 
(SNP8, 12 and 13) were determined as previously 
described[13] by denaturing high-performance liquid 
chromatography (dHPLC, Wave DNA Fragment Analysis 
System, Transgenomic Limited, UK). Sequence variation, 
observed in the dHPLC profile, was sequenced on both 
strands to confirm the alteration. Sequencing reactions 
were performed with the ABI BigDye Terminator Cycle 
Sequencing Kit v1.1 (Applied Biosystems, Foster City, 
CA) and samples were sequenced on an ABI Prism 310 
Genetic Analyzer (Applied Biosystems, Foster City, CA). 
Statistical analysis
Variables were tested for normality with Shapiro Wilk’s 
W test. t-test with separate variance estimates, χ2-test, 
χ2-test with Yates correction and likelihood ratio (LR) 
test were calculated to evaluate differences between 
various groups of  CD patients and controls, as well 
as within subgroups of  CD patients, as appropriate. 
Sensitivities, specificities, positive and negative likelihood 
ratios were calculated to determine the predictive 
power of  gASCA, AMCA, ALCA, ACCA, OMP or the 
combination of  these markers in distinguishing between 
CD and controls. Spearman’s rank order correlation 
was calculated to test the association between anti-
glycan/OMP and TGA levels. Two-sided t-test for 
independent samples with separate variance estimates 
and ANOVA with post hoc Scheffe test were used to 
analyze the association between anti-glycan antibody 
titers and clinical symptoms at diagnosis. A P value of  < 
0.05 was considered as significant. For statistical analysis, 
SPSS15.0 (SPSS Inc, Chicago, IL) was used with the help 
of  a statistician (Dr. Peter Vargha).
RESULTS
Presence of anti-glycan and anti-OMP antibodies at the 
time of diagnosis of celiac disease
The frequency and the mean titers of  gASCA IgG, 
AMCA IgG, and ACCA IgA were significantly higher at 
the time of  diagnosis of  CD than in healthy and non-
celiac gastrointestinal control groups (Table 1, Figure 1). 
However, the frequency of  ALCA IgG and anti-OMP 
IgA positivity and also the mean titers in the patients 
were similar to those in control groups. No difference 
was found between healthy subjects and GI controls 
based on the presence of  these antibodies. For that 
reason, we only used the healthy subjects as a control 
group in the subsequent comparisons. 
When calculating the sensitivity and specificity of  the 
different markers based on the cut-off  values suggested 
by the manufacturer, 65.9% of  the CD patients were 
positive for at least one of  the tested anti-microbial 
antibodies at the time of  diagnosis. Except ALCA, 
all anti-glycan antibodies were specific for untreated 
CD. However, the overall sensitivity was low (gASCA: 
39.0%, AMCA: 35.4%, ACCA: 37.8%). The above 
association was further tested by using the LR test. The 
sensitivity, specificity, positive and negative LR between 
CD at diagnosis and controls are presented in Table 2. 
Compared to healthy controls, gASCA, AMCA, and 
ACCA were associated with a moderate increase in the 
likelihood of  CD, respectively. The positivity of  any anti-
glycan antibody significantly increased the likelihood for 
untreated CD (Table 2). 
Detailed clinical data on the symptoms at the time 
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Figure 1  Anti-microbial antibody levels in 190 patients with celiac disease and in control groups. Individual values are shown by black spots. Mean values with 
standard error bars are indicated in gray. Cut-off values for positivity are pointed out by dotted line and 50, 100, 60, 90 and 25 U/mL for gASCA IgG, AMCA IgG, ALCA 
IgG, ACCA IgA and OMP IgA, respectively.
Table 1  Frequency of anti-microbial antibodies in 190 patients with celiac disease and in control groups  n  (%)
 Group 1 Group 2 Group 3 Control GI control
n              82                33                75              100                48
TGA IgA (U/mL) (median; IQR)        54.3 (20.2-100.0)        32.2 (9.9-73.1)       2.7 (2.2-3.7) – –
gASCA IgG positive     32 (39.0)b,f,j        12 (36.3)d,f,l    10 (13.3) 14 (14)    2 (4.2)
AMCA IgG positive      29 (35.4)b,f,j,n    3 (9.1)    1 (1.3) 0 (0) 0 (0)
ALCA IgG positive 7 (8.5) 0 (0) 0 (0) 6 (6)    1 (2.1)
ACCA IgA positive      31 (37.8)b,f,j,n      4 (12.1)    3 (4.2) 6 (6)    1 (2.1)
Any glycan positive       54 (65.9)b,f,j,p        15 (45.4)d,f,l 15 (20) 21 (21)    4 (8.4)
Anti-OMP IgA positive 22 (26.8)    11 (33.3)    23 (30.7) 20 (20)    11 (22.9)
TGA: Antibodies against transglutaminase; Group 1: Celiac patients at the time of diagnosis; Group 2: Celiac patients after starting a gluten-free diet 
but still with celiac antibody positivity; Group 3: Celiac patients on a long-term strict gluten-free diet; Control: Healthy control; GI control: Non-celiac 
gastrointestinal disease control. Cut-off levels used for the determination of positivity were according to the manufacturers’ guidelines: 50, 100, 60, 90 U/mL 
and 25 U/mL for gASCA IgG, AMCA IgG, ALCA IgG, ACCA IgA, and anti-OMP IgA, respectively. bP < 0.001, dP < 0.01, group 1 or Group 2 vs control; fP 
< 0.001, group 1 or Group 2 vs GI control; jP < 0.001, lP < 0.01, group 1 or Group 2 vs Group 3; nP < 0.001, pP < 0.03, group 1 vs Group 2. Using χ2-test with 
Yates correction.
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of  diagnosis in Group CD1 was available in 78 patients 
out of  82. Of  the 78 patients, 32 (41%) presented with 
severe malabsorption, 34 (43.6%) with non-specific or 
minor gastrointestinal symptoms, 9 (11.5%) with iron 
deficiency anemia, and 3 (3.9%) with other symptoms. 
The titers of  the anti-glycan antibodies varied according 
to the presenting symptoms (Table 3) by 2-sided t-test for 
independent samples with separate variance estimates. If  
the above association was tested by ANOVA and post hoc 
Scheffe-test only the association for gASCA (P = 0.027) 
and AMCA (P = 0.03) remained significant. Moreover, the 
clinical presentations of  CD were distributed differently 
according to serological response (Figure 2, Table 4). 
Patients with severe malabsorption more frequently had 
multiple antibodies (P = 0.019) while in those with non-
specific gastrointestinal symptoms or iron deficiency 
anaemia no seroreactivity or reactivity against only one 
glycan components was more commonly seen (Table 4). 
Out of  the CD patients with multiple antibodies positivity, 
65.4% were diagnosed because of  malabsorption, which 
was significantly higher than in CD patients with another 
serotype group (0 = 26.9%, or 1 = 34.8%, P = 0.019) 
(Figure 2). 
Correlation between anti-glycan and anti-OMP 
antibodies and TGA or EMA
A significant correlation was found between anti-glycan 
and TGA levels (PgASCA < 0.001, R = 0.39; PAMCA = 0.01, 
R = 0.28; PALCA = 0.006, R = 0.23; PACCA < 0.0001, R = 
0.53; PantiOMP = 0.001, R = 0.25 by Spearman’s rank order 
correlation). Similarly, a positive association was found 
between EMA IgA and gASCA (P < 0.001), AMCA (P 
< 0.001), ACCA (P < 0.0001), or any-glycan (P < 0.0001) 
but not with anti-OMP positivity.
The effect of strict gluten-free diet on anti-glycan and 
anti-OMP antibody positivity
In the group of  30 patients who were evaluated both at 
diagnosis and following a long term GFD (subgroup of  
Group CD1), initial positivity for anti-glycan antibodies 
(gASCA in 12, AMCA in 9, and ACCA in 11 patients) 
observed at diagnosis was lost after GFD. The titer of  
each antibody decreased significantly after adherence to 
GFD (P < 0.001 for each). Anti-OMP antibody positivity 
behaved similarly, with all but one of  14 patients positive 
at diagnosis becoming negative after GFD. The one 
patient who did not become negative during a 135 month-
long period of  GFD did in fact decrease during GFD 
from 33.2 to a borderline positive value of  25.4 units (a 
positive result is defined as ≥ 25 units).
The level of  the different antibodies was also 
significantly lower after GFD (P < 0.001 for each). 
Figure 3 shows individual anti-glycan and anti-OMP 
antibody titers at the time of  diagnosis and their changes 
Table 2  Predictive power of serological markers for 
distinguishing between patients with celiac disease at the time 
of diagnosis and various control groups
Sensitivity 
(%)
Specificity 
(%)
95% CI
LR+ LR-
Celiac disease vs healthy controls
   gASCA 39 86 2.73 (1.57-4.76) 0.71 (0.59-0.86)
   AMCA 35       100 - -
   ACCA 38 94 6.36 (2.76-14.4) 0.66 (0.56-0.79)
   Any glycans 66 79 3.13 (2.08-4.73) 0.43 (0.31-0.59)
Celiac disease vs non-celiac gastrointestinal controls
   gASCA 39 96 9.36 (2.35-37.4) 0.64 (0.53-0.76)
   AMCA 35       100 - -
   ACCA 38 98  18.1 (2.56-128.5) 0.64 (0.53-0.76)
   Any glycans 66 92 7.90 (3.05-20.4) 0.37 (0.27-0.51)
Table 3  Association between the titer of anti-microbial 
antibodies and the leading clinical symptoms at the time of 
celiac disease presentation (in Group 1, n  = 781)
Malabsorption Non-specific 
gastrointestinal 
Anaemia
n 32 34 9
gASCA IgG 54.8 (16.4-99.4)b    21.3 (7.1-76.5) 12.2 (8.8-36.7)
AMCA IgG   90.3 (59.5-115.9)b    73.8 (52.3-104.4)a   44.1 (25.1-55.0)
ALCA IgG 20.6 (16.7-31.2)b 23.7 (16.5-39.1)a 12.8 (9.9-15.2)
ACCA IgA 103.8 (53.3-192.1)b    57.3(37.4-100.5)a   26.8 (12.7-53.6)
OMP IgA     14.8 (5.2-33.2)    15.2 (8.2-24.2) 16.2 (2.9-34.1)
1Detailed clinical data were not available for 4 patients, data of 3 patients 
with other symptoms are not shown; aP < 0.005, bP < 0.01, between patients 
with non-specific gastrointestinal symptoms or malabsorption and anaemia 
by t-test for independent samples with separate variance estimates.
Table 4  Occurrence of multiple antibody responses to 
microbial antigens in untreated celiac disease patients in 
relation to the number of responses against microbial antigens 
n  (%) (n  = 78)
0 1 2 to 4 Total
Severe malabsorption   7 (22)   8 (25) 17 (53) 32 (40)
Non-specific gastrointestinal 
symptoms
13 (38) 12 (35)  9 (27) 34 (44) 
Iron deficiency anemia   6 (67)   3 (33) 0   9 (12)
Others 2 0 1 3 (4)
Total 28 (36) 23 (29) 27 (35)   78 (100)
P = 0.019 by χ2-test. Clinical data were not available for 4 patients.
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Figure 2  Clinical presentation of celiac disease according to serological 
response.
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after successful adherence of  to the GFD. 
The frequency of  antibodies directed against glycans 
and the mean antibody titers were significantly lower in 
patients with successful adherence to GFD (Group CD3) 
than in untreated patients (Group CD1) (Table 2, Figure 1) 
and did not differ statistically from healthy controls. 
Prevalence of NOD2/CARD15 mutations and their 
association with antibody titers and symptoms at 
presentation
The prevalence of  NOD2/CARD15 mutation in CD 
(19/134, 14.2%) did not differ from that in the control 
group (16/100, 16%). Additionally, we did not observe 
any association between symptoms at presentation or 
anti-glycan antibody positivity and the presence of  
NOD2/CARD15 variants (data not shown). 
DISCUSSION
This is the first report to investigate the complex 
associations between a panel of  new serological markers, 
clinical presentation of  the disease, and NOD2/CARD15 
status in a relatively large cohort of  CD patients. 
Furthermore, direct comparison between the anti-
microbial responses in this CD group and our similarly 
tested previous Crohn’s disease cohort[15] can be made 
to add new pieces to the puzzle of  the anti-microbial 
antibody formation.
In this study, we demonstrated that the presence of  
anti-glycan antibodies (gASCA, ACCA, and AMCA) are 
associated with CD at the time of  diagnosis. However 
the prevalence of  ALCA and anti-OMP did not dif-
fer from the results in the control group. The rate of  
gASCA positivity (39%) at the time of  diagnosis of  CD 
was comparable to the results in CD patients in previ-
ous studies[22-26]. Based on previous results a sample size 
of  42-66 celiac patients and controls would have been 
needed to confirm the above difference with an alpha 
error of  5% and a statistical power of  95%. In fact, in 
the present study, for celiac disease at diagnosis the alpha 
error was 3% and the statistical power 97%.
We could not concur with the findings of  Candelli 
et al[26] and Barta et al[33], which showed significant differ-
ences in the prevalence of  ASCA IgG between CD and 
Crohn’s diseases. In contrast, no significant difference was 
noted between the two groups (39% vs 50.5%, P = 0.091). 
In the present study, except ALCA, the occurrence of  
other anti-glycan antibodies and their median titers in CD 
at diagnosis was also similar to those observed in Crohn’s 
disease[13,34] (celiac disease gASCA: 33.1 U/mL, AMCA 
79.3 U/mL, ALCA 21.5 U/mL, ACCA 68.4 U/mL vs 
Crohn’s disease gASCA: 48.3 U/mL, AMCA 55.5 U/mL, 
ALCA 25.4 U/mL, ACCA 46.2 U/mL). In addition, the 
positivity rate for any anti-glycan antibody was also com-
parable in these patient groups (CD vs Crohn’s disease: 
65.9% vs 59.4%, P = NS). In addition, sensitivity, specific-
ity, positive and negative likelihood ratios in celiac disease 
are comparable to that observed in Crohn’s disease. Con-
sequently, in patients with gastrointestinal symptoms, the 
presence of  gASCA, AMCA, or ACCA may not only sug-
gest underlying Crohn’s disease but may also be associated 
with untreated CD. At the same time, and based on our 
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results, ALCA and anti-OMP proved to be specific but 
relatively non-sensitive markers for Crohn’s disease. 
Current data advocate that in both CD and Crohn’s 
disease patients have a primary defect in intestinal perme-
ability that is also shared by a subgroup of  relatives. In 
CD, it is also apparent that the exposure to gluten results 
in mucosal inflammation and the consequent tissue dam-
age further abrogating the primary gut barrier defect, 
while gluten removal resolves the enhanced intestinal 
permeability[35,36]. These gliadin-induced mechanisms are 
proposed to be the cause of  the anti-microbial antibodies 
formation in the disease and is strongly supported by the 
association found between anti-glycan markers and TGA 
or EMA in the present study and also that the antibody 
status is substantially altered following the introduction 
of  GFD. gASCA and other positive anti-glycan antibodies 
were entirely lost in our cohort of  CD patients, after strict 
adherence to long-term GFD. These results are concor-
dant with previous findings[20,22]. In the study of  Mallant-
Hent et al[24], ASCA IgG or IgA positivity disappeared in a 
substantial number but not the all of  the 111 patients on a 
strict GFD (from 28.8% to 8.1%). A possible explanation 
for this difference could be that the mean follow up pe-
riod after GFD was longer in our study [49 (10-159) mo 
vs 33 (range 3-113) mo]. These results suggest that as the 
period of  strict GFD increases, so is the greater disap-
pearance of  antibody positivity, which will supposedly 
lead to entire mucosal healing in the small intestine. The 
higher prevalence of  ASCA in adults compared to chil-
dren further underlines the important role of  long-lasting 
inflammation and consequently antigen exposure in the 
formation of  anti-microbial antibodies.
In the present study, we also established that the kinet-
ics of  antibody disappearance is variably sensitive to the 
length of  GFD. Of  the anti-glycan antibodies, AMCA 
and ACCA declined most rapidly, right after the TGA 
titer started to diminish. In Group CD2, the prevalence 
of  these antibodies had already changed as compared to 
Group CD1, from approximately 36% to 11%, while the 
frequency of  gASCA and anti-OMP remained unchanged. 
Among those CD patients who adopted a strict GFD, 
the duration of  GFD was the shortest in this group. In 
the group of  patients with a successful response to GFD 
(Group CD3), the frequency of  gASCA as well as AMCA 
and ACCA was also lower. At the same time, the overall 
frequency of  anti-OMP did not change, either in group 
CD2 or in CD3 (Table 1). We showed however, that the 
level of  anti-OMP clearly declined to normal in 13 of  the 
14 anti-OMP positive CD patients when specific patients 
in group CD1 were followed (Figure 2). The explanation 
of  this supposedly inconsistency may be that the mean 
follow-up in both groups CD2 and CD3 was significantly 
shorter than in those in group CD1 participating in intra-
individual longitudinal monitoring, suggesting that anti-
OMP requires the longest time to disappear completely 
and this occurs long after the normalization of  TGA and 
EMA. The differences in the evolution of  anti-OMP and 
anti-glycan antibodies in IBD has also justified our find-
ings in this patient group[15].
We evaluated the possible relationship between sero-
logical response and the clinical presentation of  the dis-
ease. Patients with multiple seroreactivity to glycans, more 
commonly presented with severe malabsorption as com-
pared to those without any reactivity against any glycan 
at all (63% vs 22%, P = 0.019), and accounted for 53% 
of  all malabsorption cases. Among the patient groups, 
the TGA titer reached the highest value (115.9 U/mL vs 
others: 60.9 U/mL, P = 0.016) in those presenting with 
malabsorption, further supporting enhanced intestinal 
permeability as a likely component involved in antibody 
formation. It is well known that the intestinal damage is 
most pronounced in the malabsorption cases and TGA is 
a good marker for tissue injury[37]. We must note however, 
that the number of  subjects in different clinical presen-
tation groups were limited, thus further studies with a 
larger cohort of  CD patients are needed to confirm these 
findings.
Recent data suggest that the presence of  anti-microbial 
antibodies might be linked to genetic susceptibility. In 
patients with Crohn’s disease an association was found 
between antimicrobial formation and the carriage of  
mutations in innate immunity receptor genes (NOD2/
CARD15 or toll-like receptor)[15,20]. However, in the 
absence of  NOD2 variants in our Crohn’s patients’ 
cohort, the gASCA and the any-glycan positivity was 
also reasonably high (43.5% and 53.7%, respectively). 
Furthermore, among CD patients in the present study we 
found that these antibodies occur with the same frequency 
and magnitude as in patients with Crohn’s disease, albeit 
the occurrence of  NOD2/CARD15 mutation was 
significantly lower. These findings - alongside with the 
fact that there is no association between TLR4 variants 
and CD[38,39] - do not support the primary role of  genetic 
predisposition in antibody formation. Nevertheless, the 
presence of  NOD2/CARD15 was associated with an 
increased antibody formation in Crohn’s disease and 
an apparent link was also reported between increased 
permeability and NOD2/CARD15 3020insC mutation[40]. 
We did not observe any association between anti-
glycan antibody positivity and the presence of  NOD2/
CARD15 variants in CD. However, the limited number 
of  subjects carrying NOD2/CARD15 mutations might 
not have allowed us to recognize significant differences in 
serological response in this patients group. An inheritable 
trait of  anti-microbial antibody formation is unlikely in 
CD, since we did not find a higher prevalence of  ASCA 
(9.1% vs 14%) and anti-OMP (12.1% vs 20%) as compared 
to the controls in the 66 unaffected, first-degree relatives 
(siblings) of  this cohort. 
On the basis of  significant similarity in the qualitative 
and quantitative serological response in the two patients’ 
groups, we hypothesize a similar mechanism for the for-
mation of  the anti-microbial antibody formation in both 
celiac disease and Crohn’s disease. The presence of  sero-
logical response might be the reflection of  the sustained 
exposure to the constituent of  the gut microflora due to 
the enhanced bacterial translocation. The known predis-
posing factors for bacterial translocation, such as bacterial 
overgrowth in the small bowel (secondary to intestinal 
dysmotility)[41-43], the damage to the integrity of  the gut 
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mucosa (secondary to alterations of  the local intestinal 
microvasculature)[44,45], which results in reduced oxygen 
delivery and an increased formation in oxygen radicals[46] 
as well as the upregulation of  the proinflammatory cyto-
kines, such as tumor necrosis factor α, interleukin-17 or 
interferon gamma in active lesions[47], and the defective 
mucosal immunological defense[21,48] are all typical features 
in both clinical conditions. The significance of  the en-
hanced bacterial translocation out of  the small bowel in 
the anti-microbial antibody formation is further supported 
by the fact that the presence of  the serological response 
among patients with Crohn’s disease is mainly characteris-
tic for those with complicated (stricturing or penetrating) 
small bowel involvement and is rarely observed in the 
isolated colonic disease or in patients with ulcerative coli-
tis. At the same time, the recovered gut barrier function 
protects against the invasion of  microbes or their compo-
nents leading to the cessation of  anti-microbial antibody 
formation. In CD, this process may be justified by the 
observation that the serological response is a temporary 
phenomenon. As a result of  the discontinuation of  glia-
din exposure and the subsequent mucosal healing, the an-
tibodies disappear completely. Confirming this aspect of  
our hypothesis is much more complicated in Crohn’s dis-
ease. First of  all, the pathogenetic processes are not only 
multifaceted but also less characterized as compared to 
CD. The complete elimination of  the causative agents is 
not possible. Moreover, no such reliable serological mark-
ers are available reflecting the extent of  gut inflammation 
as TGA and anti-actin IgA antibodies in CD. Finally, in 
terms of  the complete loss of  microbial seroreactivity, the 
long-lasting complete remission (without mucosal inflam-
mation) is mandatory but rarely reached in patients with 
Crohn’s disease as compared to CD patients adhering to 
a strict GFD. In this point of  view, findings reporting a 
lack of  solid correlation between disease activity and the 
presence or the magnitude of  seroreactivity[17,49] in Crohn’s 
disease can not be in opposition to our hypothesis any 
more. The advent of  the new biological treatments might 
answer this unresolved question, since the complete mu-
cosal healing in Crohn’s disease can be achieved with this 
therapy in a greater proportion of  cases than with classical 
drugs. At this moment, however, no data from prospective 
studies are available addressing the effect of  the biological 
therapy on antibody stability. Our data also call for ad-
ditional basic research to explore the exact mechanism of  
immune responses to commensal enteric bacteria as well 
as the possible clinical significance of  the bacterial trans-
location in the pathogenesis or the complications of  these 
diseases as it is well established in other clinical conditions 
such as liver cirrhosis, acute pancreatitis or sepsis[50].
In conclusion, our results suggest that ASCA and other 
anti-glycan antibodies may be considered as additional 
markers for CD and adherence to a GFD. Furthermore, 
the presence and the magnitude of  response to microbial 
components is associated with a more severe clinical 
course but not with mutations in NOD2/CARD15. This 
seroreactivity may be the consequence of  the enhanced 
bacterial translocation through the impaired small bowel 
mucosa.
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